Vanda Pharmaceuticals Inc
SWB:VM4
Vanda Pharmaceuticals Inc
SWB:VM4
Price:
6.4
EUR
4.07%
Market Closed
Market Cap:
€825m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
V
|
Vanda Pharmaceuticals Inc
SWB:VM4
|
US |
|
Cicor Technologies Ltd
LSE:0QPR
|
CH |
|
C
|
Canadian Tire Corporation Ltd
SWB:YAAA
|
CA |
|
Besqab AB (publ)
STO:BESQ
|
SE |
|
H
|
Humana Inc
LSE:0J6Z
|
US |
|
D
|
Dcm Shriram Industries Ltd
BSE:523369
|
IN |
Balance Sheet
Balance Sheet Decomposition
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc
Balance Sheet
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc
Currency: USD
| Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||||
| Cash & Cash Equivalents |
7
|
16
|
21
|
31
|
42
|
39
|
205
|
43
|
88
|
89
|
65
|
61
|
51
|
40
|
34
|
61
|
45
|
61
|
52
|
135
|
136
|
102
|
85
|
|
| Cash Equivalents |
7
|
16
|
21
|
31
|
42
|
39
|
205
|
43
|
88
|
89
|
65
|
61
|
51
|
40
|
34
|
61
|
45
|
61
|
52
|
135
|
136
|
102
|
85
|
|
| Short-Term Investments |
0
|
0
|
10
|
1
|
43
|
7
|
0
|
156
|
61
|
32
|
66
|
69
|
92
|
101
|
110
|
196
|
267
|
307
|
381
|
332
|
252
|
272
|
179
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
1
|
2
|
1
|
2
|
4
|
16
|
20
|
18
|
29
|
26
|
30
|
33
|
34
|
34
|
47
|
55
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
1
|
2
|
1
|
2
|
4
|
16
|
20
|
18
|
29
|
26
|
30
|
33
|
34
|
34
|
47
|
55
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
5
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
|
| Other Current Assets |
0
|
0
|
2
|
2
|
2
|
1
|
2
|
2
|
3
|
4
|
3
|
3
|
6
|
12
|
8
|
12
|
15
|
10
|
12
|
18
|
9
|
15
|
27
|
|
| Total Current Assets |
7
|
17
|
33
|
34
|
87
|
48
|
213
|
201
|
154
|
126
|
136
|
142
|
167
|
174
|
170
|
299
|
354
|
409
|
478
|
519
|
433
|
439
|
347
|
|
| PP&E Net |
1
|
1
|
1
|
2
|
1
|
2
|
1
|
1
|
1
|
2
|
2
|
2
|
5
|
5
|
5
|
4
|
15
|
15
|
12
|
11
|
9
|
13
|
14
|
|
| PP&E Gross |
1
|
1
|
1
|
2
|
1
|
2
|
1
|
1
|
1
|
2
|
0
|
0
|
5
|
5
|
5
|
4
|
15
|
15
|
12
|
11
|
9
|
13
|
14
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
2
|
1
|
2
|
2
|
3
|
3
|
1
|
0
|
0
|
2
|
3
|
5
|
5
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
11
|
10
|
8
|
7
|
5
|
27
|
39
|
28
|
26
|
25
|
23
|
22
|
20
|
19
|
121
|
114
|
117
|
|
| Long-Term Investments |
0
|
0
|
1
|
0
|
8
|
0
|
0
|
0
|
19
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
1
|
1
|
1
|
3
|
3
|
4
|
4
|
92
|
88
|
83
|
85
|
85
|
91
|
11
|
|
| Total Assets |
8
N/A
|
18
+112%
|
36
+101%
|
36
+1%
|
97
+167%
|
50
-49%
|
226
+352%
|
213
-6%
|
183
-14%
|
135
-26%
|
143
+6%
|
172
+20%
|
213
+24%
|
210
-1%
|
205
-2%
|
332
+62%
|
484
+46%
|
534
+10%
|
594
+11%
|
634
+7%
|
648
+2%
|
656
+1%
|
489
-25%
|
|
| Liabilities | ||||||||||||||||||||||||
| Accounts Payable |
1
|
1
|
2
|
3
|
3
|
1
|
2
|
1
|
1
|
0
|
1
|
1
|
5
|
5
|
4
|
5
|
6
|
6
|
6
|
5
|
2
|
41
|
2
|
|
| Accrued Liabilities |
0
|
1
|
3
|
6
|
10
|
3
|
2
|
1
|
3
|
5
|
5
|
6
|
46
|
46
|
39
|
48
|
54
|
60
|
69
|
87
|
85
|
97
|
130
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
27
|
29
|
27
|
27
|
27
|
0
|
0
|
0
|
27
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
|
| Total Current Liabilities |
1
|
2
|
5
|
9
|
13
|
3
|
32
|
31
|
32
|
32
|
33
|
8
|
51
|
50
|
70
|
53
|
60
|
66
|
74
|
91
|
88
|
100
|
145
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
171
|
144
|
118
|
93
|
66
|
3
|
29
|
29
|
4
|
4
|
13
|
14
|
14
|
16
|
16
|
15
|
13
|
|
| Total Liabilities |
1
N/A
|
2
+29%
|
5
+183%
|
10
+86%
|
13
+38%
|
4
-70%
|
203
+5 097%
|
175
-13%
|
149
-15%
|
126
-16%
|
99
-21%
|
11
-89%
|
80
+634%
|
79
-1%
|
74
-6%
|
57
-23%
|
73
+28%
|
80
+10%
|
89
+11%
|
107
+20%
|
104
-3%
|
118
+14%
|
162
+37%
|
|
| Equity | ||||||||||||||||||||||||
| Common Stock |
10
|
28
|
62
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
3
|
12
|
36
|
100
|
174
|
225
|
261
|
254
|
263
|
291
|
308
|
288
|
328
|
346
|
361
|
336
|
221
|
197
|
164
|
158
|
155
|
174
|
395
|
|
| Additional Paid In Capital |
0
|
0
|
24
|
127
|
258
|
271
|
284
|
291
|
297
|
301
|
352
|
449
|
461
|
477
|
493
|
612
|
631
|
650
|
669
|
686
|
700
|
713
|
721
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
|
| Other Equity |
0
|
0
|
19
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
7
N/A
|
16
+127%
|
31
+93%
|
27
-13%
|
84
+212%
|
46
-45%
|
23
-50%
|
38
+64%
|
34
-11%
|
10
-70%
|
44
+345%
|
161
+265%
|
133
-17%
|
131
-1%
|
131
+0%
|
275
+110%
|
411
+49%
|
453
+10%
|
505
+11%
|
527
+4%
|
545
+3%
|
539
-1%
|
327
-39%
|
|
| Total Liabilities & Equity |
8
N/A
|
18
+112%
|
36
+101%
|
36
+1%
|
97
+167%
|
50
-49%
|
226
+352%
|
213
-6%
|
183
-14%
|
135
-26%
|
143
+6%
|
172
+20%
|
213
+24%
|
210
-1%
|
205
-2%
|
332
+62%
|
484
+46%
|
534
+10%
|
594
+11%
|
634
+7%
|
648
+2%
|
656
+1%
|
489
-25%
|
|
| Shares Outstanding | ||||||||||||||||||||||||
| Common Shares Outstanding |
22
|
22
|
22
|
22
|
27
|
27
|
28
|
28
|
28
|
28
|
33
|
42
|
43
|
44
|
45
|
53
|
54
|
55
|
56
|
57
|
58
|
58
|
59
|
|
Switch to:
Switch to:
See Also
Other Vanda Pharmaceuticals Inc listings:
Discover More
